Quick Answer
Sonoma Pharmaceuticals, Inc. reported Operating Income of -$3.71 million for fiscal year 2025.
Sonoma Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$3.71M | +21.1% |
| 2024 | -$4.70M | -2.9% |
| 2023 | -$4.57M | +22.4% |
| 2022 | -$5.89M | -70.7% |
| 2021 | -$3.45M | +53.3% |
| 2020 | -$7.39M | +34.4% |
| 2019 | -$11.26M | +20.7% |
| 2018 | -$14.19M | -9.4% |
| 2017 | -$12.97M | +11.8% |
| 2016 | -$14.71M | -121.0% |
| 2015 | -$6.66M | -10.0% |
| 2014 | -$6.05M | -79.3% |
| 2013 | -$3.37M | +47.8% |
| 2012 | -$6.47M | +13.8% |
| 2011 | -$7.50M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$678.0K | +34.2% | -101.2% |
| September 30, 2025 | -$337.0K | +60.4% | +69.2% |
| June 30, 2025 | -$1.09M | +6.6% | -6.2% |
| December 31, 2024 | -$1.03M | -22.2% | -21.3% |
| September 30, 2024 | -$850.0K | +29.6% | +27.5% |
| June 30, 2024 | -$1.17M | +5.4% | -39.0% |
| December 31, 2023 | -$844.0K | +54.0% | +30.1% |
| September 30, 2023 | -$1.21M | -65.3% | +2.6% |
- Sonoma Pharmaceuticals, Inc. showed an increase of +21.1% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, Sonoma Pharmaceuticals, Inc.’s operating income has grown by 50.6% (from -$7.50 million to -$3.71 million).
- The most recent figure is from Sonoma Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: